Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi74-vi76; doi:10.1093/annonc/mdm230
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Orlando, L
Right arrow Articles by Cinieri, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlando, L
Right arrow Articles by Cinieri, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast and ovarian cancer

Management of advanced breast cancer

L Orlando1, M Colleoni1, P Fedele2, A Cusmai2, P Rizzo2, M D'Amico2, MC Chetri2 and S Cinieri2,3,*

1 Unit of Research Medical Senology, European Institute of Oncology, Milano
2 Medical Oncology Division, Brindisi
3 Ematoncology Division, European Institute of Oncology, Milano, Italy

* Correspondence to: Dr S. Cinieri, Medical Oncology Division, ASL BR, Brindisi, Italy. Tel: +39-0831-537218; Fax: +39-0831-537918; E-mail: saverio.cinieri{at}auslbr1.it

Metastatic breast cancer (MBC) is usually considered an incurable situation, for which treatments chosen to control the disease, should take into account the maintenance of a good quality of life. The end points of treatment of patients with MBC are influenced by consideration about efficacy and toxicity of the different therapeutic options. The availability of markers predicting response to treatment as well as the discovery of new agents have led to the identification of patients likely to obtain significant advantage from different treatment options. Due to the chronic nature of the MBC, the clinical benefit which encompasses objective response and long stabilization of disease has often become a goal in the metastating setting.

Key words: metastatic breast cancer, predictive factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. Yang, A. Boire, A. Agarwal, N. Nguyen, K. O'Callaghan, P. Tu, A. Kuliopulos, and L. Covic
Blockade of PAR1 Signaling with Cell-Penetrating Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis
Cancer Res., August 1, 2009; 69(15): 6223 - 6231.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. M. Goldblatt, E. R. Gentry, M. J. Fox, S. M. Gryaznov, C. Shen, and B.-S. Herbert
The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel
Mol. Cancer Ther., July 1, 2009; 8(7): 2027 - 2035.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.